Pulmonary Disease and Transplant Pathology: From Molecular Mechanisms to Diagnosis

Dear Colleagues,

Although the underlying mechanisms of human lung pathology leading to end-stage lung disease have historically been poorly studied, significant advances have been made in recent years, in particular using genomic approaches in addition to well-established investigative methods. Besides the three most common diseases causing end-stage lung disease, namely cystic fibrosis, bronchiectasis and emphysema, other genetic and interstitial lung diseases have been defined. However, little is known about how the underlying molecular mechanisms leading to end-stage lung disease impact the pulmonary allograft and outcome of lung transplantation.

This Special Issue aims to showcase original research and reviews on the latest innovations in diagnostic tools to classify the underlying cause of end-stage pulmonary disease, the relevance for patient management, medical therapy, adverse events and the outcome of the pulmonary allograft in view of lung allograft dysfunction.

Through this Special Issue, we aim to provide a platform for clinicians, pathologists, researchers and other professionals to highlight advances and emerging trends in this field, enhancing knowledge and directing the development of biomarkers, including machine learning and artificial intelligence.

You may choose our Joint Special Issue in the Life.

Dr. Katharina Wassilew
Dr. Izidor Kern
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• end-stage lung disease
• lung transplantation
• immunology
• molecular testing
• clinicopathological correlation
• adverse events, outcome
• emerging technologies